Literature DB >> 28426320

Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.

Anh Thu Bui1, Meng-Er Huang2, Maryline Havard1, Fanny Laurent-Tchenio1, François Dautry1, Thierry Tchenio1.   

Abstract

Cellular quiescence is a reversible cell growth arrest that is often assumed to require a persistence of non-permissive external growth conditions for its maintenance. In this work, we showed that androgen could induce a quiescent state that is self-sustained in a cell-autonomous manner through a "hit and run" mechanism in androgen receptor-expressing prostate cancer cells. This phenomenon required the set-up of a sustained redox imbalance and TGFβ/BMP signaling that were dependent on culturing cells at low density. At medium cell density, androgens failed to induce such a self-sustained quiescent state, which correlated with a lesser induction of cell redox imbalance and oxidative stress markers like CDKN1A. These effects of androgens could be mimicked by transient overexpression of CDKN1A that triggered its own expression and a sustained SMAD phosphorylation in cells cultured at low cell density. Overall, our data suggest that self-sustained but fully reversible quiescent states might constitute a general response of dispersed cancer cells to stress conditions.

Entities:  

Keywords:  Androgen; BMP; CDKN1A; cellular quiescence; feedback loops; oxidative stress; prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28426320      PMCID: PMC5444360          DOI: 10.1080/15384101.2017.1310345

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  44 in total

1.  Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.

Authors:  Harri Makkonen; Miia Kauhanen; Tiina Jääskeläinen; Jorma J Palvimo
Journal:  Mol Cell Endocrinol       Date:  2010-08-20       Impact factor: 4.102

2.  Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway.

Authors:  Wei He; David C Dorn; Hediye Erdjument-Bromage; Paul Tempst; Malcolm A S Moore; Joan Massagué
Journal:  Cell       Date:  2006-06-02       Impact factor: 41.582

3.  A novel model of dormancy for bone metastatic breast cancer cells.

Authors:  Rebecca Marlow; Gabriella Honeth; Sara Lombardi; Massimiliano Cariati; Sonya Hessey; Aikaterini Pipili; Veronica Mariotti; Bharath Buchupalli; Katie Foster; Dominique Bonnet; Agamemnon Grigoriadis; Pranela Rameshwar; Anand Purushotham; Andrew Tutt; Gabriela Dontu
Journal:  Cancer Res       Date:  2013-10-21       Impact factor: 12.701

4.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

5.  IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2.

Authors:  S Hubackova; A Kucerova; G Michlits; L Kyjacova; M Reinis; O Korolov; J Bartek; Z Hodny
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

6.  Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Authors:  Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chieh Huo; Chiech Huo; Liang-Cheng Su; Shutsung Liao
Journal:  Cancer Sci       Date:  2011-08-18       Impact factor: 6.716

7.  Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.

Authors:  E G Langeler; C J van Uffelen; M A Blankenstein; G J van Steenbrugge; E Mulder
Journal:  Prostate       Date:  1993       Impact factor: 4.104

8.  Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.

Authors:  Paul Thelen; Elmar Heinrich; Felix Bremmer; Lutz Trojan; Arne Strauss
Journal:  Prostate       Date:  2013-07-19       Impact factor: 4.104

9.  Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-05       Impact factor: 11.205

10.  TGF-β/NF1/Smad4-mediated suppression of ANT2 contributes to oxidative stress in cellular senescence.

Authors:  Miroslava Kretova; Ludmila Sabova; Zdenek Hodny; Jiri Bartek; Gabriel Kollarovic; Buck D Nelson; Sona Hubackova; Katarina Luciakova
Journal:  Cell Signal       Date:  2014-09-16       Impact factor: 4.315

View more
  4 in total

1.  Molecular determinants of response to high-dose androgen therapy in prostate cancer.

Authors:  Michael D Nyquist; Alexandra Corella; Osama Mohamad; Ilsa Coleman; Arja Kaipainen; Daniel A Kuppers; Jared M Lucas; Patrick J Paddison; Stephen R Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  JCI Insight       Date:  2019-10-03

2.  Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death.

Authors:  Zhendong Xiang; Yin Sun; Bosen You; Meng Zhang; Chiping Huang; Junfeng Yu; Xiangyun You; Denglong Wu; Chawnshang Chang
Journal:  Cell Death Dis       Date:  2021-01-11       Impact factor: 8.469

3.  Discovery proteomics defines androgen-regulated glycoprotein networks in prostate cancer cells, as well as putative biomarkers of prostatic diseases.

Authors:  Jordy J Hsiao; Melinda M Smits; Brandon H Ng; Jinhee Lee; Michael E Wright
Journal:  Sci Rep       Date:  2021-11-15       Impact factor: 4.379

Review 4.  Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.

Authors:  Osama S Mohammad; Michael D Nyquist; Michael T Schweizer; Stephen P Balk; Eva Corey; Stephen Plymate; Peter S Nelson; Elahe A Mostaghel
Journal:  Cancers (Basel)       Date:  2017-12-06       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.